In evaluating an enzyme-linked immunoassay of carcinoembryonic antigen (CEA) we found that the IgG fraction of polyclonal anti-CEA antibodies (DAKO) bound very well to the walls of polypropylene test tubes. We therefore developed an immunoradiometric CEA assay based on this binding of polyclonal anti-CEA antibody. We biotinylated a commercially available monoclonal antibody (Hybritech) and bound this to the CEA-anti-CEA bound to the tube wall. For detection we used 1251-labeled streptavidin. In comparison with several immunoassays for CEA this system offered several advantages such as greater linearity of the standard curve (from 0 to 74 j.g/L), a steeper dose-response curve, and smaller coefficients of variation in the clinically useful range. This assay system may be used for other large molecules, so that only one tracer, the 125l-labeled streptavidin, has to be labeled; thus the technique seems suited for several different assays.
CEA is a family of isoantigens with multiple antigen determinants.
Another difficulty of CEA assays is that some CEA-like substances that occur in serum may cross-react with the antibodies to various extents: e.g., nonspecific cross-reacting antigen, normal glycoprotein,CEA-associatad protein, coloniccarcinoembryonic antigen 2, colon carcinoma antigen ifi, beta external protein, and tumor-associated antigen (4).
Comparison of CEA assays in different tumor patients has often yielded conflicting results (5) . In setting up an enzymelinked iinmunoassay for CEA according to Goudable et al. (6), we noticed a high binding of the anti-CEA-IgG fraction to the walls of the polypropylene tubes. However, this ELISA yielded, for some healthyblood donors, CEA concentrations that exceeded the upper limit of the generally accepted normal reference interval. Suspecting some cross-reaction of the two polyclonal antibodies with CEA-like substances, we replaced the enzyme-labeled polyclonal antibody with a monoclonal antibody, which we biotinylated to simplify detection.
The resulting immunoradiometric assay has the following advantages:improved linearity and precision, absence of a high-dose "hook" effect, high signal yield by comparably low total activity, no damage of monoclonalantibodies by oxidation during labeling, small amounts of radioactive waste, and low cost per tube. AU materials involved are commercially available, and the labeled streptavidin can be used for different assays.
Materials and Methods
Samples: Serum samples were obtained from 10 mL of blood collected in tubes without anticoagulants ("Serum Monovette"; W. Sarstedt, NUmbrecht, F.RG.). All sera were stored at 2 to 8#{176}C and assayed within 72 h, or kept at -20 "C if longer storage was necessary.
For quality-control materials, we used Lyphocheck I, II, and ifi (Bio-Rad Laboratories, Munich, F.R.G. 
Immunoradiometnc Assay with Avidin-Biotin Labeling
Coating: After diluting 100 pL of anti-CEA (IgG fraction, DAKO) in 39.9 mL of distilled water (final concentration, 25 mg/L), we put 200 pL into each radioimmunoassay tube (Sarstedt, cat. no. 731055) and incubated them at 4#{176}C overnight. We then washed each tube three times with 500 pL of isotonic saline. Kept frozen at -20 "C, these coated tubes can be used for longer than 12 months.
Biotinylation of monoclonal antibody: We conjugated biotin-NHS and biotin-XNHS to the monoclonal antibody preparation from Hybritech, using a 10 to 1 molar ratio of biotin to protein. These were mixed by use of a pipette and incubated overnight in the dark at room temperature.
To remove any unincorporated biotin, we filtered the mixtures three times through a Centricon C30 ultrafilter (Amicon, Witten, F.R.G.) with a 30 000-Da cutoff. We used phosphate buffer (pH 7.4,60 mmol!L) for washing. The final volume of the concentrate was 50 pL. The biotinylated monoclonal anti-CEA was retained but the unincorporated biotin passed through the ifiter and was discarded. The biotinylated monoclonal antibody was finally diluted to 1 mL with the phosphate buffer. Stored at -20 "C, it is usable for longer than a year, and it served as the stock solution.
Assay buffer: This was phosphate buffer (60 mmolfL, pH 7.4) containing 1 g of sodium azide, 0.4 g of EDTA, and 20 g of bovine serum albumin per liter.
Assay Procedure
After washing the anti-CEA antibody-coated tubes with isotonic saline, add 100 pL of standard, control, or patient's sample to each tube, plus 100 pL of assay buffer. Cover the tubes tightly with adhesive tape, mix the contents of the tubes, centrifuge briefly(30 s, 2000 rpm), and incubate at 37 "C in a water bath for 4 h. Aspirate the contents of the tubes, wash the tubes three times with isotonic saline, and add 200 pL of 600-fold diluted stock solution of biotinylated monoclonal antibody, using assay buffer for dilution. Count the radioactivity bound to the test tube walls with a gamma counter.
To determine the optimal concentration of biotinylated monoclonalanti-CEA antibody, we tested various dilutions of stock solution, from 50-to 6400-fold. to the biotinylated monoclonal antibody was considerably improved in the presence of the spacer. In further experiments, therefore, we conjugated only biotin-XNHS to the monoclonal antibody. Figure 1 also shows that the binding was optimal at 200 ng of biotinylated antibody per tube.
Results

Coating
Kinetics of streptavidinibiotin binding: Although the affinity of avidin for biotin is high enough (Km = iO' L/mol) that in liquid-phase assays 15 mm oftensuffices for complete binding, Figure 2 shows that solid-phase assays require more time to give efficient results. Therefore we used an incubation time of 4 h for this step.
Standard curve: The final set-up of the assay gives a typical standard curve as shown in Figure 3 tions are very high-and a less-steep standard curve are obtained if standards or samples and the biotinylated monoclonal antibody are incubated together instead of sequentially. As Figure 4 shows, no hook effect appears at CEA concentrations up to 10 mg/L if the assay is performed under sequential conditions (4 h + 20 h + 4 h).
When we measured a serum sample with a CEA concentration of approximately 10 mg/L in various dilutions, results for each dilution at a concentration above the upper limit of the standard curve remained "off curve." Higher CEA concentrations are rare, so we do not anticipate falsely low results owing to a high-dosehook effect.
Statistical quality control: We measured several samples with different CEA concentrations to determine reproducibility; the coefficients of variation (CVs) ranged between 4.3% and 8% (Table 1) . We then compared the Abbott CEA-ELISA, the Boehringer CEA-EUSA, the CEA-EU8A of Goudable et al. (6), and our CEA biotin-streptavidin-ntrt, using all to study 145 patients' samples, divided into four groups according to CEA concentration: group 1,26 samples <1 p.g/ L; group II, 60 samples between 1 and 5 .tg/L; group ifi: 36 samples between 5 and 15 p.g/L; and group IV, 23 samples between 15 and 80 g/L. The results, expressed as coeffidents of correlation, are shown in Table 2 .
The CEA ELISA with DAKO antibodies (6)frequently measured too-high CEA concentrations, especially in the low-concentration groups I and H (CEA <5 g/L): for 13 samples CEA concentrations exceeded 5 pg/L (maximum 19 jgfL), whereas the other assays yielded results <5 tg/L, in five cases <2 tg/L. In addition, for a group of 20 healthy blood donors, the CEA concentrations obtained with the Abbott ELISA were <2 ig/L, whereas the ELISA with DAKO antibodies yielded CEA concentrations >5 p.g/L in six cases, one of these at 18.8 tg/L.
Discussion
Although radioimmunoassay was initially the technique used for determining CEA (1,2,9), antibody-excess methods such as inununoradiometric assays or enzyme-linked immunoabsorbent assays have been established in recent years because of their shorter incubation times and higher precision. When we were attemptingto set up and evaluate the ELISA of Goudable et al. (6), which seems very simple and straightforward, we noticed an insufficient specificity of the method that had not been mentioned previously. The use of two polyclonal antibodies from one species (rabbit) obviously does not offer the specificity required for CEA determination because several cross-reacting substances are present (4). In attempting to set up this ELISA, we improved the coating of the polypropylene immunoassay tubes by simply diluting the IgG fraction of anti-CEA in distilled water and incubating overnight at 4#{176}C. To increase specificity, we used a commercially available monoclonal antibody, which we initially iodinated (results not shown). However, to decrease the need for radiolabeling and the oxidative damage normally occurring during most such labeling procedures,we triedbiotinylating the monoclonal antibody, and we used radiolabeled streptavidin as the marker. Thus the antibodies used were not damaged and retained their immunological properties. We used streptavidin instead of avidin because of the lower nonspecific binding of the former to plastic tube walls. Comparison of the conjugation of biotin and biotin a-aminocaproic acid to the monoclonal antibody showed that labeled streptavidin more strongly bound the latter conjugate, presumably because of less steric hindrance.
The time course of binding in this solid-phase system is slower than in a liquid-phase system. We used fairly long incubation intervals to reach an endpoint of binding. Sequential incubation obviated a high-dose hook effect and yielded a steeper standard curve. Prolonging the first incubation period from 4 h to 24 h did not improve the standard curve significantly. Commercial ELISA'S ordinarily involve relatively short incubation times, 1 or 2 h; however, they may not reach steady-state conditions and may therefore be less reproducible and their standard curves may be nonlinear. In our opinion, determinations of CEA should be as accurate and reproducible as possible to detect small, early increases in CEA concentrations in serum. Because patients are monitored monthly or less often, and because follow-up treatment (e.g., surgery) is sometimes based solely on a time-dependent increase of CEA concentration, the quality of the assays should not be sacrificed for speed.
Under optimal conditions the standard curve was linear between CEA concentrations of 0.7 and 73.4 tgfL, and 56% of the total radioactivity was bound at 320 tg/L. CVs in the Roche CEA-RIA were 5% to 15% (10), in the Abbott CEA-IRMA 9% to 16% (11), and elsewhere they were <10% or <13% (2, 9) . The CVs in the present assay were between 4.3% and 8%.
Other advantages of the newly developed CEA assay involving the avidin-biotin system include: 1. Biotinylation diminishes alterations to the antibody compared with oxidative radiolabeling, so thereis no loss of immunoreactivity.
2. This system may be transferable to other assays requiring just one radioactively labeled substance, 'I-labeled streptavidin.
Thus the variety of assays performed in one laboratory may be increased, or a great number of antibodies can be tested for different purposes in a very short time.
3. Biotinylated antibody can be stored for at least one year, whereas radiolabeling has to be repeated every month. The decrease in the number of substances that have to be labeled-labeling of streptavidin only-is a great advantage.
In healthyblood donors (n = 20), we detected low CEA concentrations with this assay, as we did with the Abbott and Boehringer ELISA's, in contrast to the ELISA with two polyclonal antibodies (6).
